BDBM603696 US11654147, Compound 15::US11654147, Compound 346::US11654147, Compound 351::US11654147, Compound 45

SMILES COc1cc2c(ccnc2cc1F)-c1cnn2cc(cnc12)N1CCC(CC1)N1CCN(C)CC1

InChI Key InChIKey=UYQADNMBNQEQQG-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 603696   

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 18nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 19nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 24nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 102nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 372nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 1.52E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 2.82E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 4.21E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 8.93E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603696(US11654147, Compound 15 | US11654147, Compound 351...)
Affinity DataIC50: 1.04E+4nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent